KRAS and familial pancreatic carcinoma: However, FTase inhibitors (FTIs) exhibited disappointing results in clinical trials toward to pancreatic cancer, which mainly possess KRAS mutation [65–67], and subsequent research revealed KRAS and NRAS gained alternative modifications by geranylgeranyltransferases (GGTase) in cells treated with FTIs [68].